Dependence of the thermoluminescent high-temperature ratio (HTR) of LiF:Mg,Ti detectors on proton energy and dose

The high-temperature ratio (HTR) is a parameter quantifying changes of the shape of the high-temperature part of the LiF:Mg,Ti glow-curve after exposure to densely ionizing radiation. It was introduced in order to estimate the effective LET of an unknown radiation field and to correct the decreased relative TL efficiency for high Linear Energy Transfer (LET) radiation. In the present work the dependence of HTR on proton energy (14.5 to 58 MeV) and dose (0.5 to 30 Gy) was investigated. All measured HTR values were at the level of 1.2 or higher, therefore significantly different from the respective value for gamma rays (HTR is equal to 1), but HTR was found to be insensitive to changes of proton energy above 20 MeV. As a result the relationship between HTR and relative TL efficiency is not unequivocal. The HTR was found to be dependent on absorbed dose even for the lowest studied doses.Comment: Manuscript has been presented at the 17th International Conference on Solid State Dosimetry, Recife, Brasil, September 22-27,201

Thermoluminescence fading studies: Implications for long-duration space measurements in Low Earth Orbit

Within a 1.5 year comprehensive fading experiment several batches of LiF:Mg,Ti and LiF:Mg,Cu,P thermoluminescence detectors (TLDs) were studied. The TLDs originated from two manufacturers and were processed by three laboratories using different annealing and readout conditions. The TLDs were irradiated with two radiation modalities (gamma-rays and thermal neutrons) and were stored at two temperatures (-17.4C and +18.5C). The goal of the experiment was to verify the stability of TLDs in the context of their application in long-term measurements in space. The results revealed that the response of all TLDs is stable within 10% for the studied temperature range. No influence of the radiation type was found. These results indicate that for the properly oven-annealed LiF TLDs, fading is not a significant problem, even for measuring periods longer than a year

Some clinical applications of MTS-type TLD detectors

An important part of any QA programme for radiotherapy is verification, in vitro or in vivo, of calculated doses and dose distributions. We studied the clinical applicability of LiF:MG, Ti sintered TL detectors produced, as type MTS-N, by the Institute of Nuclear Physics in Kraków (INP). These are solid pellets of diam 4.5mm and 0.8mm thickness. The TL reader was a modified planchet-type 770A, also produced at the INP, with linear heating and computerised glow curve recording.For analysis of in vivo applications, we measured, in a water phantom, the dose at 14 points aroud the Standard gynaecological applicator of our SELECTRON LDR/MDR afterloading unit with Cs-137 pellets and compared the measured values with doses calculated at these points by the in-house developed SELKOM computer code used for planning gynaecological brachytherapy at the Centre of Oncology in Kraków (COK). Agreement to within 5% was stated.To demonstrate the applicability of MTS dosemeters in calibration dosimetry, we studied the accuracy, stability and reproducibility of a batch of 100 detectors over several readout cycles at doses ranging from 0.5 to 2.5 Gy. At 1 Gy, the relative standard deviation of Individual Calibration Factors (ICF) over six readout cycles did not exceed 2.5% indicating that the error of dose estimation using individual MTS detectors should not exceed 2%.In an intercomparison of Co-60 beams at the COK and at Louvain performed with MTS detectors agreement to within less than 0.5% was found with an accuracy better than 1%.This work is partly supported by KBN Polish State Committee for Scientific Research, Research Project No. 8T11E02908

Validation of modelling the radiation exposure due to solar particle events at aircraft altitudes

Dose assessment procedures for cosmic radiation exposure of aircraft crew have been introduced in most European countries in accordance with the corresponding European directive and national regulations. However, the radiation exposure due to solar particle events is still a matter of scientific research. Here we describe the European research project CONRAD, WP6, Subgroup-B, about the current status of available solar storm measurements and existing models for dose estimation at flight altitudes during solar particle events leading to ground level enhancement (GLE). Three models for the numerical dose estimation during GLEs are discussed. Some of the models agree with limited experimental data reasonably well. Analysis of GLEs during geomagnetically disturbed conditions is still complex and time consuming. Currently available solar particle event models can disagree with each other by an order of magnitude. Further research and verification by on-board measurements is still neede

The problems associated with the monitoring of complex workplace radiation fields at European high-energy accelerators and thermonuclear fusion facilities

The European Commission is funding within its Sixth Framework Programme a three-year project (2005-2007) called CONRAD, COordinated Network for RAdiation Dosimetry. The organisational framework for this project is provided by the European Radiation Dosimetry Group EURADOS. One task within the CONRAD project, Work Package 6 (WP6), was to provide a report outlining research needs and research activities within Europe to develop new and improved methods and techniques for the characterisation of complex radiation fields at workplaces around high-energy accelerators, but also at the next generation of thermonuclear fusion facilities. The paper provides an overview of the report, which will be available as CERN Yellow Repor

24. Validation of conformal radiotherapy treatment planning systems using an antro-pomorphic phantom and thermoluminescence dosimetry

Within the requirements of a Quality Assurance programme in a radiotherapy department, the ability of a treatment planning system (TPS) to accurately calculate dose distributions under realistic conditions encountered in radiotherapy (RT) should be validated. This may be accomplished by thermoluminescence (TL) dosimetry in simulated treatment of antropomorphic phantoms. In our radiotherapy department, several planning systems are used concurrently in 3D conformal treatment of larger volumes (with irregular fields obtained via individual shielding or multileaf collimation) and of very small volumes (stereotactic technique), by external megavoltage photon beams. Realistic 3D treatment plans were prepared using CadPlan, Theraplan and BrainLab TPS for treating volumes in an Alderson phantom, which was prepared for topometry (CT-scanned) and irradiated in fully simulated conditions of patient RT. Suitably selected TL detectors (some custom-produced for these measurements), were placed inside and around the treated volumes in the phantom. For every photon beam applied (Co-60, 6 MV or 9 MV) the TL detectors, individually corrected, were calibrated in a standard solid phantom against ionisation chamber dosimetry. For irradiation of larger volumes, standard MTS-N (LiF:Mg,Ti) detectors were used. For stereotactic irradiation of small volumes in the head (6 MV) special miniature thermoluminescent LiF:Mg,Ti and LiF:Mg,Cu,P were developed. The technique of detector calibration, preparation of Alderson phantom for simulated RT, detector readout and interpretation of the measured versus calculated values of dose at measurement points inside the phantom, will be described

Protective role of vitamin B6 (PLP) against DNA damage in Drosophila models of type 2 diabetes

Growing evidence shows that improper intake of vitamin B6 increases cancer risk and several studies indicate that diabetic patients have a higher risk of developing tumors. We previously demonstrated that in Drosophila the deficiency of Pyridoxal 5' phosphate (PLP), the active form of vitamin B6, causes chromosome aberrations (CABs), one of cancer prerequisites, and increases hemolymph glucose content. Starting from these data we asked if it was possible to provide a link between the aforementioned studies. Thus, we tested the effect of low PLP levels on DNA integrity in diabetic cells. To this aim we generated two Drosophila models of type 2 diabetes, the first by impairing insulin signaling and the second by rearing flies in high sugar diet. We showed that glucose treatment induced CABs in diabetic individuals but not in controls. More interestingly, PLP deficiency caused high frequencies of CABs in both diabetic models demonstrating that hyperglycemia, combined to reduced PLP level, impairs DNA integrity. PLP-depleted diabetic cells accumulated Advanced Glycation End products (AGEs) that largely contribute to CABs as α-lipoic acid, an AGE inhibitor, rescued not only AGEs but also CABs. These data, extrapolated to humans, indicate that low PLP levels, impacting on DNA integrity, may be considered one of the possible links between diabetes and cancer